)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
PMV Pharmaceuticals
PMV Pharmaceuticals (PMVP) investor relations material
PMV Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Rezatapopt remains the lead precision-oncology program; no product revenue, with substantial R&D spending and recurring losses.
PYNNACLE Phase 2 ovarian cancer primary-analysis enrollment is complete; Q1 2027 accelerated-approval NDA submission is planned.
Rezatapopt showed a 46% investigator-assessed ORR in the ovarian efficacy population; a pivotal-cohort update is planned for a late-breaking ENA 2026 presentation.
Financial highlights
Q3 R&D was $16.1M and G&A $4.0M; operating expenses were $20.1M, down from $22.5M YoY.
Q3 net loss was $34.4M vs. $21.1M YoY; 2026 included a $12.8M warrant fair-value loss and $2.3M in warrant-related offering costs.
9M R&D was $46.1M vs. $54.1M, G&A $11.9M vs. $12.9M, and net loss $70.5M vs. $59.7M.
9M operating cash use was $52.4M vs. $56.4M in 2025; no product revenue has been generated.
Outlook and guidance
Cash, cash equivalents and marketable securities of $108.5M are expected to fund planned operations into Q1 2028; estimates depend on assumptions that may prove incorrect.
Initial accelerated-approval NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer is planned for Q1 2027.
PYNNACLE ovarian-cohort primary-analysis data and cohort updates are planned for a late-breaking oral presentation at ENA 2026.
Operating expenses and losses are expected to remain substantial as clinical development, regulatory work and commercialization preparation advance.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from PMV Pharmaceuticals
- Ovarian cancer data support a planned 1Q2027 rezatapopt NDA, with cash runway into 1Q2028.PMVP
Corporate presentation - Rezatapopt demonstrates strong efficacy in PROC with launch and expansion plans well underway.PMVPH.C. Wainwright 28th Annual Global Investment Conference
- Phase 2 trial completed, NDA planned Q1 2027, cash runway into Q2 2027, funding risks persist.PMVPQ2 2026
- Interim phase II data for Y220C p53 solid tumors expected July-August, with robust enrollment.PMVPTD Cowen's 6th Annual Oncology Innovation Summit
- Directors elected, executive pay approved, and auditor ratified; all proposals passed.PMVPAGM 2026
- Q1 2026 net loss was $18.0M; cash runway extends through Q2 2027 as rezatapopt advances in trials.PMVPQ1 2026
- Rezatapopt shows 46% ORR in ovarian cancer; NDA submission planned for Q1 2027.PMVPTD Cowen 46th Annual Health Care Conference
- Key votes include director elections, executive pay, and auditor ratification.PMVPProxy filing
- Director elections, executive pay, and auditor ratification headline the annual meeting agenda.PMVPProxy filing
Next PMV Pharmaceuticals earnings date
Q4 20265 Mar, 2027
PMV Pharmaceuticals
Next PMV Pharmaceuticals earnings date
Q4 20265 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
PMV Pharmaceuticals Inc. is a U.S.-based biotechnology company focused on the discovery and development of targeted therapies for cancer. The company specializes in precision oncology, aiming to create treatments that address specific genetic mutations in cancer cells. Its work spans early-stage drug discovery through clinical development. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.